First published

The plasma rollout. The repeat-order test.

Explore this signal

Long Term at a glance

Short reader summary

CSL plans to move its US plasma centres to Haemonetics equipment by end-2027. Machines could lead to repeated disposable-kit orders, but the agreement promises no minimum purchases. Watch actual installations, paid kit sales and cash after rollout costs. The same customer previously contributed to lost sales. This is a research watch, not a buy call, and no current executable entry price is recorded.

Exact asset or item

Haemonetics Corporation ordinary shares

Asset type

Listed investment

Reference price

121.34

Currency code

USD

Price observed at

2026-11-16T16:00:00-05:00

What this number represents

Tracking price

What remains unproven

Historical regular-session close, not a current executable entry or OTR purchase. The planned CSL transition has no minimum purchase commitment; actual deployment, kit orders and after-cost cash remain unproven.

Exact asset or item

Exact asset or item

Haemonetics Corporation ordinary shares

Asset type

Listed investment

Ticker

HAE

Exchange

NYSE

How to identify this exact asset

Haemonetics Corporation ordinary shares, NYSE: HAE. United States; US dollars. This is a conditional two-year research watch, not ownership of plasma, a buy call or a promise that a customer project will finish.

Price and what it means

Entry or reference price

121.34

Currency code

USD

Price observed at

2026-11-16T16:00:00-05:00

What this number represents

Tracking price

Price evidence status

Indicative

Price source

Haemonetics quant report, November 16: last close $121.34

Publisher: QDD Research

Original language: English

Reading access: partial

Underlying origin: HAE-PRICE

published date precision: day

retrieved date precision: day

Source publication date 2026-11-16

Source retrieval date 2026-11-18

Matching price source ID

HAE-PRICE

Purchase, sale and realised profit

First post-issue executable broker quote: UNAVAILABLE. The original source recorded a historical US$121.34 regular-session close on 16 November 2026 at 16:00 EST, observed on 17 November SGT. That is vendor history, not a current bid, ask or observed purchase. No purchase, sale, dividend receipt or investment return is recorded.

The developments we connected

Separate development

  1. What changed

    Customer rollout plan, not completed installation

    Date of the development

    Evidence status

    Observed

    What the evidence shows

    On 8 October 2026, CSL said it expected its US centres to transition to Haemonetics devices by end-2027. That is a customer-confirmed plan, not completed installation. The issuer's same-day 8-K also describes a scope and schedule that can change.

    Date precision is day only. The stated end-2027 target is a plan, not evidence of completed deployment.

    Source IDs

    • HAE-CSL
    • HAE-8K
  2. What changed

    Quarterly results and earlier customer-transition context

    Date of the development

    Evidence status

    Observed

    What the evidence shows

    The 2026 annual report attributes about US$153 million of prior-year sales that did not recur to the earlier CSL transition and a separate divestiture together. Do not assign that whole amount to CSL. This historical combination is not a forecast of how much revenue the renewed relationship will recover.

    The annual-report historical context is included here for comparison; it is not a new 5 November event. Quarter ended 26 September 2026. Date precision of these public disclosures is day only; no event hour is invented.

    Source IDs

    • HAE-10K
    • HAE-10Q
    • HAE-Q2

Emerging insight

Haemonetics makes machines that collect plasma, the liquid part of blood used to make medicines, and the single-use parts needed for each collection. A machine can be sold or placed once; its continuing use could support repeated disposable-kit orders. That is the opportunity worth testing. A customer's plan to change equipment does not show that the machines arrived, kits were ordered or invoices were paid.

The same large customer supplies both the warning and the possibility. The 2026 annual filing records earlier sales lost during CSL's transition. CSL's 8 October 2026 statement now sets an expected move of its US centres to Haemonetics systems by the end of 2027. Yet Haemonetics' 5 November filing says the new agreement is non-exclusive and has no minimum purchase commitment. A target date is not an order guarantee.

The narrower insight is therefore not simply 'plasma demand grows'. It is whether installed systems lead to recurring kit sales and cash after equipment, inventory, support and financing costs. Latest quarterly sales rose, but stronger cash also benefited partly from timing of payments made and customer collections. Repeated comparable results are more useful than assuming one strong quarter lasts for years.

A collection machine creates a possible installed base. Each subsequent collection may need a disposable kit, but only actual customer buying makes that recurring revenue. Installation, use, kit purchase and cash collection are different stages. CSL's own statement is a distinct customer voice about its plan; it does not independently confirm that future orders or shareholder profits have already arrived.

Four different stages, not one completed result
View evidence links
Four different stages, not one completed result
EvidenceWhat it supportsWhat still needs proof
CSL 8 October statementCustomer rollout plan to end 2027Actual installed centres and schedule delivery
Customer-confirmed installationsEquipment deployed, when verifiedKit buying and utilisation
Paid repeat kit ordersRecurring commercial activity, when verifiedProfitable margins after costs
Comparable post-rollout cashBusiness value, when verifiedDurability and shareholder return at actual entry
Only the plan is established here. Non-exclusive supply/no minimum purchases. Conditional later stages are not reported completed outcomes.
Sources
  • Original HAE research source and CSL customer plan · 17 November 2026 source issue; historical customer statement 8 October

How this exact asset could benefit

Haemonetics historically earns from equipment and disposable supplies. If CSL deploys the systems and repeatedly buys kits at profitable prices, the relationship could support continuing sales rather than only one equipment delivery. But the agreement does not oblige a minimum level of purchasing and does not exclude other suppliers.

Machines, installation, staff, inventory and customer support require spending before the full return is visible. The company reported US$200 million outstanding on its revolving credit facility at 26 September 2026. The revolver borrowing was used to settle 2026 convertible notes, not established as borrowing caused by the CSL rollout. Total debt was US$1,123.761 million and cash US$260.712 million at 26 September, giving a derived net debt of US$863.049 million. The US$200 million facility balance is not total debt. Higher sales are less valuable if financing and working-capital needs absorb the cash.

Shareholders could benefit only if lasting profit and cash improve and the share price paid leaves room for a return. A better business result can still be a poor investment at an expensive entry. No fair-value estimate, price target or probability of profit is established here.

Who could benefit

  1. Who

    Haemonetics

    How they could benefit

    Actual installed systems could support repeated disposable-kit purchases, provided pricing and costs permit lasting cash generation.

    Evidence status

    Still unproven

  2. Who

    HAE shareholders

    How they could benefit

    Only sustained earnings/cash and a suitable actual entry price could support shareholder returns; a better company result is not automatically a good investment.

    Evidence status

    Still unproven

What we observed

The 5 November 2026 quarterly release reported US$357.8 million of sales, up 9.3%, and US$103.8 million of free cash flow. Timing of both payments made and customer collections helped the cash result. These are company-wide reported figures, not verified revenue or free cash generated by the future CSL rollout.

For balance, reported net income rose to US$46.3 million from US$38.7 million, and reported operating margin rose to 21.0% from 17.9%. Adjusted operating margin was 26.3%, down 40 basis points. Management raised revenue-growth guidance to 8–11% from 5–8%, but reduced the expected adjusted-margin expansion to 0–50 basis points from 50–100. Stronger sales guidance and narrower margin expectations can coexist.

A stronger quarter is not proof of rollout cash
View comparison values
A stronger quarter is not proof of rollout cash
MeasurePrior-year quarterQuarter ended 26 September 2026
Reported net income, US$ million38.746.3
Reported operating margin, %17.921.0
Adjusted operating margin, %26.726.3
Prior adjusted margin 26.7% derived from current 26.3% down 40 basis points. Do not mix currency and percentages on one numeric axis. Quarterly sales 357.8 m up 9.3%; no invented rounded prior-revenue comparator. Results predate 8 October target announcement, not proof of rollout-attributable cash.
Sources
  • Haemonetics Q2 FY2027 financial results · 5 November 2026

The quarter ended 26 September, before the 8 October expanded-rollout target announcement. It may include activity under the August agreement, but these results do not demonstrate cash attributable to the expanded rollout. The US$103.8 million figure is company-defined free cash flow, which deducts capital expenditure and additions to Haemonetics equipment net of disposals; it is not a simplistic operating-cash-minus-capex calculation.

What remains unproven

The strongest counter-evidence is in the agreement: non-exclusive supply and no minimum purchases. Historical CSL-related sales loss shows concentration risk, while payment timing cautions against treating one quarter's cash as normal. An announcement is not independent confirmation of realised deployment or paid demand.

Unknowns include installed-centre counts, actual paid kit volumes, pricing, margin, rollout spending, sustained cash conversion, competitive responses and current executable entry. No independent commercial outcome proves the thesis yet.

What to check before acting

Entry conditions

The historical US$121.34 close is not an offer that an ordinary reader can accept now. A decision would require a dated broker bid and ask, applicable fees, FX and tax, plus a valuation grounded in actual earnings and risk. The source contains no reliable post-publication executable entry. A missing original entry cannot later be filled with a convenient historical price and called a realised return.

Possible upside

Upside: CSL installs the systems across most US centres, purchases recurring disposable kits and Haemonetics turns those orders into durable cash after rollout spending.

Possible downside

Middle: installation progresses, but costs and competitive pricing offset some gains. Downside: CSL changes the plan, delays deployment, uses competing systems or buys fewer kits than expected. HAE shares could lose substantial value, including the possibility of total investment loss. No future asset prices or scenario probabilities are assigned.

Price or return range method

No future asset prices, scenario probabilities, fair-value estimate or return range are supported. The invented trading arithmetic is teaching material only, not an HAE return forecast.

Costs and fees

For this US-dollar share, consider broker access, bid/ask spread, commissions, SGD/USD movement, tax, customer concentration, debt and liquidity. This dossier is about shares, not physical plasma or collectible inventory. No account-specific trading-cost schedule or tax treatment was verified.

Illustration only: ten shares bought at an invented US$120 and sold at an invented US$130 produce US$100 before costs. Deduct invented US$10 trading fees and US$10 currency costs to leave US$80 before tax. These are teaching numbers, not HAE transaction prices, observed trades or a return forecast. Actual net investment performance remains unavailable.

How hard it may be to sell

Listed share access does not guarantee an executable price or adequate liquidity at the desired time. No current bid, ask, spread, volume or account-specific fee schedule was verified.

Key risks

Customer concentration, non-exclusive supply, no minimum purchases, competition, deployment delays, working capital, equipment spending, debt and USD/SGD changes can weaken the thesis. Missing disclosure is not proof of success or verified economic failure.

What an ordinary reader can do next

Put HAE on a research list. In each quarterly report, read the Plasma and Apheresis discussion and keep disclosed machine deployments, kit sales and customer payments separate. Do not use the end-2027 calendar target as evidence that CSL paid an invoice.

Compare sales, gross margin, working-capital movements, borrowing and free cash flow across several reports. Ask whether cash improvement comes from repeated business or the timing of collections. Keep the 2026 annual report as a record of what can happen when a large customer changes systems.

The first scheduled review is 17 May 2027; results may arrive sooner. Before any independent investment decision, obtain an actual broker quote and costs. Research can proceed without purchasing the shares.

Original forecast record

Original forecast in full

CSL’s planned return to Haemonetics plasma systems could bring repeated paid kit sales after installations, but value for HAE shareholders depends on actual orders, margins and cash after rollout costs, not the announced end-2027 target.

The original six dates and test wording are frozen. They are conditional checks, not price targets; evidence can arrive before a formal review. Main horizon: two years, 17 November 2028.

UNRESOLVED / NOT YET DUE. Original issue and freeze: 17 November 2026, 16:23:19 SGT. Main horizon 17 November 2028. No original purchase, sale, completed future outcome or verified investment return. Append later evidence while preserving the original claim, six dates and failed outcomes.

17 November 2026, 16:23:19 SGT: issue and evidence cutoff. Original retrieval window approximately 16:13–16:22 SGT on 17 November; exact per-source seconds unavailable. Historical overseas market timestamps retain their original timezone; review-calendar dates use Singapore Time. This is historical long-term research, not a claimed new 24-hour event.

The exact tests are preserved above for 17 May 2027, 17 November 2027, 17 November 2028, 17 November 2029, 17 November 2030 and 17 November 2031. No future milestone is marked completed. Dated installation records, comparable reports and actual sales/cash evidence must support later assessments.

Six frozen dates for testing the business result
  1. 2027-05-17Check dated CSL installation updates and new kit shipments. Weakens if installations stall or revenue fails to rise from a comparable base.
  2. 2027-11-17Seek customer-confirmed installed centres, recurring disposable sales and invoicing. Weakens if the end-2027 target is already materially delayed.
  3. 2028-11-17After the claimed 2027 rollout, compare paid kit revenue, margins and cash after investment. Weakens if deployment has no profitable repeat cash.
  4. 2029-11-17Check repeat-order durability and customer concentration. Weakens if CSL reduces orders or inventory and equipment costs keep rising.
  5. 2030-11-17Review debt, shareholder dilution and free cash across a downturn. Weakens if the revenue gain required expensive permanent financing.
  6. 2031-11-17Compare five annual reports with the frozen 2026 thesis. Weakens if the rebound was temporary or cash returns were insufficient.
Research checkpoints, not share-price targets. Main horizon 17 Nov 2028; no completed outcome or original trade.
Sources
  • Original HAE research source and CSL customer plan · 17 November 2026 source issue; historical customer statement 8 October

Check customer-confirmed installation progress, disposable-kit buying, invoicing and actual cash generation, with a consistent comparison base. Distinguish company-wide sales and cash from CSL-specific effects, and payment timing from recurring conversion. Follow inventory, equipment spending, interest, debt, dilution and concentration over several periods. A new announcement without deployment, paid demand or after-cost value is not a completed outcome.

Frozen original rule: By 2028-11-17, no substantive verified CSL deployment and repeat kit sales, or deployment without improved after-cost cash over comparable reports. Mark partly following only if installation is real but profits remain unproven.

Apply the whole evidence test, not a single weak share-price day. Missing data is not proof of success; no observed purchase means no realised OTR investment return. The original claim and dates remain unchanged.

Publication-clock clarification: 17 November 2026 at 16:23:19 SGT is the source issue and evidence cutoff, not a claim that this native article was publicly published then. Preserve the actual first native publication receipt separately. Failure-rule clarification: preserve the original rule verbatim; insufficient disclosure is unassessable, not established failure. Verified weak after-cost economics is different from profits that are merely not yet proved. Partly following requires genuinely mixed confirming evidence.

Original forecast date and time

2026-11-17T16:23:19+08:00

Forecasts and review dates

6 months

Review date

2027-05-17

Original forecast

Check dated CSL installation updates and new kit shipments. Weakens if installations stall or revenue fails to rise from a comparable base.

What to measure

Check dated CSL installation updates and new kit shipments.

What must happen

Later dated, comparable evidence must establish the operating development described in the original test. A calendar target or share-price move alone does not satisfy it.

What would challenge the forecast

Weakens if installations stall or revenue fails to rise from a comparable base.

Current outcome

Not yet due

1 year

Review date

2027-11-17

Original forecast

Seek customer-confirmed installed centres, recurring disposable sales and invoicing. Weakens if the end-2027 target is already materially delayed.

What to measure

Seek customer-confirmed installed centres, recurring disposable sales and invoicing.

What must happen

Later dated, comparable evidence must establish the operating development described in the original test. A calendar target or share-price move alone does not satisfy it.

What would challenge the forecast

Weakens if the end-2027 target is already materially delayed.

Current outcome

Not yet due

2 years

Review date

2028-11-17

Original forecast

After the claimed 2027 rollout, compare paid kit revenue, margins and cash after investment. Weakens if deployment has no profitable repeat cash.

What to measure

After the claimed 2027 rollout, compare paid kit revenue, margins and cash after investment.

What must happen

Later dated, comparable evidence must establish the operating development described in the original test. A calendar target or share-price move alone does not satisfy it.

What would challenge the forecast

Weakens if deployment has no profitable repeat cash.

Current outcome

Not yet due

3 years

Review date

2029-11-17

Original forecast

Check repeat-order durability and customer concentration. Weakens if CSL reduces orders or inventory and equipment costs keep rising.

What to measure

Check repeat-order durability and customer concentration.

What must happen

Later dated, comparable evidence must establish the operating development described in the original test. A calendar target or share-price move alone does not satisfy it.

What would challenge the forecast

Weakens if CSL reduces orders or inventory and equipment costs keep rising.

Current outcome

Not yet due

4 years

Review date

2030-11-17

Original forecast

Review debt, shareholder dilution and free cash across a downturn. Weakens if the revenue gain required expensive permanent financing.

What to measure

Review debt, shareholder dilution and free cash across a downturn.

What must happen

Later dated, comparable evidence must establish the operating development described in the original test. A calendar target or share-price move alone does not satisfy it.

What would challenge the forecast

Weakens if the revenue gain required expensive permanent financing.

Current outcome

Not yet due

5 years

Review date

2031-11-17

Original forecast

Compare five annual reports with the frozen 2026 thesis. Weakens if the rebound was temporary or cash returns were insufficient.

What to measure

Compare five annual reports with the frozen 2026 thesis.

What must happen

Later dated, comparable evidence must establish the operating development described in the original test. A calendar target or share-price move alone does not satisfy it.

What would challenge the forecast

Weakens if the rebound was temporary or cash returns were insufficient.

Current outcome

Not yet due

Sources

Dated source

  1. Source ID

    HAE-10K

    What this source supports

    Haemonetics |2026 Annual Report / Form 10-K
    Fiscal year ended 28 March 2026; English, USA. Historical CSL transition plus divestiture explains combined nonrecurring sales, not future recovery. Issuer filing. Original recorded access window approximately 16:13–16:22 SGT on 17 November; exact per-source seconds unavailable. Source-author and later publisher/reviewer read scopes are attributed, not independently reopened by this mapping worker. Fiscal year-end is not the publication date; original filing publication day is unavailable in this package.

    Later provenance check on 17 November 2026: the issuer's filing record identifies this underlying fiscal-2026 Form 10-K as filed on 20 May 2026, separately from the 28 March period end. This date identifies the underlying filing, not an independently established annual-report cover or PDF upload date.

  2. Source ID

    HAE-CSL

    What this source supports

    CSL Limited / ASX | Update on U.S. Plasma Collection Network
    8 October 2026; English, Australia. Customer voice for proposed US transition by end-2027, not verified completed installations. Original recorded access window approximately 16:13–16:22 SGT on 17 November; exact per-source seconds unavailable. Source-author and later publisher/reviewer read scopes are attributed, not independently reopened by this mapping worker.

  3. Source ID

    HAE-10Q

    What this source supports

    Haemonetics / SEC | Fiscal 2027 second-quarter Form 10-Q
    Filed 5 November 2026; English, USA. Agreement scope, no minimum purchases, contingent timing, borrowing and reported results. Issuer-authored filing. Original recorded access window approximately 16:13–16:22 SGT on 17 November; exact per-source seconds unavailable. Source-author and later publisher/reviewer read scopes are attributed, not independently reopened by this mapping worker.

  4. Source ID

    HAE-Q2

    What this source supports

    Haemonetics / SEC Exhibit 99.1 | Q 2 FY 2027 financial results
    5 November 2026; English, USA. Quarterly sales/cash and payment-timing qualification. Same issuer as 10-Q, not independent earnings confirmation. Original recorded access window approximately 16:13–16:22 SGT on 17 November; exact per-source seconds unavailable. Source-author and later publisher/reviewer read scopes are attributed, not independently reopened by this mapping worker.

  5. Source ID

    HAE-PRICE

    What this source supports

    The dated QDD report records the November 16 US$121.34 close. The issuer's historical quote table corroborates the price: https://haemonetics.gcs-web.com/stock-information/historical-price-lookup/ . The market observation time is not the report's publication time. Not an executable price.

  6. Source ID

    HAE-8K

    What this source supports

    Haemonetics / SEC |8-K on updated CSL rollout
    8 October 2026; English, USA. Issuer disclosure that rollout scope and timing may change; tied to the same customer plan. Original recorded access window approximately 16:13–16:22 SGT on 17 November; exact per-source seconds unavailable. Source-author and later publisher/reviewer read scopes are attributed, not independently reopened by this mapping worker.

  7. Source ID

    HAE-AUG8K

    What this source supports

    Historical disclosure newly checked after the frozen source cutoff on 17 November 2026. The report says the agreement was entered into on 14 August; the 18 August disclosure initially anticipated a portion of US centres, with timing and scope undetermined and no guidance change then. This gives a distinct earlier baseline for the October expanded plan, not independent issuer confirmation or a new November commercial outcome. Full 74-line filing read; source predates the original cutoff, verification does not.

Source limits

The full new 20-page source and separate 10-page Long Term presentation reference were read for this mapping. This is not a claim that every underlying URL was independently reopened in this mapping pass. The original source states its URLs were directly opened within the recorded retrieval window; that access claim remains attributed to the source. Issuer filings and issuer releases share an origin; customer CSL supplies a separate voice for its plan, not proof of completed work. Source citations are moved to this closing register without changing the frozen claim.

Later 17 November publisher/reviewer checks reopened the earnings release, CSL statement, 8-K and historical-price page, and checked the 10-Q debt description. These add the balanced profit/margin baseline, payment-timing qualification and debt-purpose clarification; exact per-page access seconds were not supplied. The original package states that seven reviewers completed full 20-page source and 10-page reference reads; that earlier aggregate claim is subject to individual receipt reconciliation and is not newly certified here. Reviewer agreement is not external evidence.

Access recorded by original source: 17 November 2026, approximately 16:13–16:22 SGT; exact per-link second unavailable. Publication/event dates differ from access time. All six original URLs retained; descriptive labels used where exact original title is not reproduced.

Resumed verification on 17 November 2026 reconciles individual read receipts and completes missing full-source and reference reads before publication. This is actual resumed checking, not reconstructed assurance that seven complete reads happened earlier. The publisher retains the final individual completion record. Source objects preserve partial access scope; no fresh full-source audit is claimed by the mapping worker.

Additional provenance verification after the original 16:23:19 SGT cutoff: the issuer filing record establishes the underlying Form 10-K filing date as 20 May 2026. The separately dated 18 August 8-K adds historical agreement context. On the original price-history page, the 16 November close remains US$121.34; the page explicitly labels its data 'Last updated: Nov 16, 2026', distinct from page publication (unknown) and retrieval on 17 November. No original claim, horizon or entry price is reset.

The November 16 QDD report and issuer historical table were cross-checked after the original freeze. The earlier Stock Analysis historical table remains contextual corroboration, not a dated publication: https://stockanalysis.com/stocks/hae/history/ .

Back to Signals

AI powered research